🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

The First Affiliated Hospital of Nanchang University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with The First Affiliated Hospital of Nanchang University as lead sponsor. Synced 26 Sep 2026
14Current trials
11Recruiting now
3Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

The First Affiliated Hospital of Nanchang University is the lead sponsor of 14 current clinical trials in our China register. 11 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Neoantigen-based peptide vaccine, Neoantigen-loaded DC vaccine and Fruquintinib. The most-studied condition is Advanced NSCLC.

ClinicalTrials.gov trials by status

  • Recruiting1179%
  • Not yet open214%
  • Active, closed17%

Trials by phase

  • Not applicable964%
  • Phase 2214%
  • Phase 417%
  • Observational17%
  • Phase EARLY_PHASE117%
01

Clinical trials sponsored by The First Affiliated Hospital of Nanchang University

14 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
NCT06752057 · ClinicalTrials.gov ↗ · Advanced NSCLC
Not applicable Recruiting 2024-09 China
Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors
NCT05749627 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors
Not applicable Recruiting 2023-04 China
Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
NCT06751966 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC)
Not applicable Recruiting 2024-09 China
Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
NCT06751953 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC)
Not applicable Recruiting 2024-09 China
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
NCT06118762 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer
Phase 4 Recruiting 2023-10 China
Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
NCT06751940 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC)
Not applicable Recruiting 2024-09 China
Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
NCT06751914 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC)
Not applicable Recruiting 2024-09 China
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
NCT06751849 · ClinicalTrials.gov ↗ · Advanced NSCLC
Phase 2 Recruiting 2024-03 China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
NCT06752044 · ClinicalTrials.gov ↗ · Advanced NSCLC
Not applicable Recruiting 2024-09 China
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
NCT06999031 · ClinicalTrials.gov ↗ · Relapsed/Refractory, Multiple Myeloma
Phase EARLY_PHASE1 Recruiting 2024-09 China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
NCT06751901 · ClinicalTrials.gov ↗ · Advanced NSCLC
Phase 2 Recruiting 2024-03 China
Exploring the Mechanism of Severe Acute Pancreatitis Based on Metagenomics, Metabolomics and Proteomics
NCT06230432 · ClinicalTrials.gov ↗ · Acute Pancreatitis
Observational Not yet open 2024-01 China
Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial
NCT06639516 · ClinicalTrials.gov ↗ · Acute Pancreatitis
Not applicable Not yet open 2025-02 China
Efficacy and Safety of Robotic-assisted Bronchoscopy Combined With the ICNVA Strategy in Biopsy of Peripheral Pulmonary Nodules
NCT07136961 · ClinicalTrials.gov ↗ · Lung Nodules, Biopsy, Navigation, Spatial
Not applicable Active, closed 2024-12 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in The First Affiliated Hospital of Nanchang University trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in The First Affiliated Hospital of Nanchang University trials

10 conditions
Advanced NSCLC4Colorectal Cancer (CRC)4Acute Pancreatitis2Advanced Malignant Solid Tumors1Metastatic Colorectal Cancer1Lung Nodules1Biopsy1Navigation, Spatial1Relapsed/Refractory1Multiple Myeloma1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1411

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced NSCLC

SponsorTrials
Huabo Biopharm1

Sponsors with the most current trials registered for this condition.

06

Questions about The First Affiliated Hospital of Nanchang University trials

How many clinical trials does The First Affiliated Hospital of Nanchang University sponsor?

The First Affiliated Hospital of Nanchang University is the lead sponsor of 14 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are The First Affiliated Hospital of Nanchang University trials recruiting?

Yes. 11 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is The First Affiliated Hospital of Nanchang University testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Neoantigen-based peptide vaccine (4), Neoantigen-loaded DC vaccine (3) and Fruquintinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.